These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26696314)

  • 1. Reply.
    Eadie JA; Ip MS
    Retina; 2016 Feb; 36(2):e10-2. PubMed ID: 26696314
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: To PMID 24999721.
    Eadie JA; Ip MS
    Retina; 2015 Aug; 35(8):e54-5. PubMed ID: 26166802
    [No Abstract]   [Full Text] [Related]  

  • 3. Correspondence.
    Călugăru D; Călugăru M
    Retina; 2016 Feb; 36(2):e9-e10. PubMed ID: 26655619
    [No Abstract]   [Full Text] [Related]  

  • 4. Correspondence.
    Bindra CS; Sen A; Mitra A; Bhushan B
    Retina; 2015 Aug; 35(8):e54. PubMed ID: 26166801
    [No Abstract]   [Full Text] [Related]  

  • 5. Correspondence.
    Bronkhorst IH; Marinkovic M; Dijkman G; Boon CJ
    Retina; 2015 Aug; 35(8):e52-4. PubMed ID: 26166799
    [No Abstract]   [Full Text] [Related]  

  • 6. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.
    Călugăru D; Călugăru M
    Eye (Lond); 2015 Aug; 29(8):1113. PubMed ID: 25976643
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to 'Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.'.
    Lotery A; Regnier S
    Eye (Lond); 2015 Aug; 29(8):1113-4. PubMed ID: 25976640
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
    Huang P; Song Z; Sun X
    Chin Med J (Engl); 2014; 127(16):3019-23. PubMed ID: 25131244
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place?
    Hahn P; Fekrat S
    Am J Ophthalmol; 2013 Mar; 155(3):415-417.e2. PubMed ID: 23394730
    [No Abstract]   [Full Text] [Related]  

  • 12. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
    Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
    Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials: a need to better define the control group as current standard of care.
    Bakri SJ
    Ophthalmology; 2015 Mar; 122(3):443-4. PubMed ID: 25703467
    [No Abstract]   [Full Text] [Related]  

  • 14. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.
    Lotery AJ; Regnier S
    Eye (Lond); 2015 Mar; 29(3):380-7. PubMed ID: 25572584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Anti-VEGF Drugs in Retinal Vein Occlusions.
    Vilela MA
    Curr Drug Targets; 2020; 21(12):1181-1193. PubMed ID: 32342813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Macular Edema Due to Central Retinal Vein Occlusion: Another Score for Repackaged Bevacizumab.
    Bressler NM
    JAMA; 2017 May; 317(20):2067-2069. PubMed ID: 28492939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.